生物医药

分子生物学与基因工程药物

1. Changping Deng, Jiacheng Ma, Yuping Liu, Xikui Tong, Lei Wang, Jiayi Dong, Ping Shi, Meiyan Wang, Wenyun Zheng*, Xingyuan Ma*. Targeting intracellular cancer proteins with tumor-microenvironment-responsive bispecific nanobody-PROTACs for enhanced therapeutic efficacy. MedComm. 2025, 19;6(2): e70068.（IF:10.70; JCR Q1）
2. Yunhui Fu#, Yiwen Zhou#, Yiying Chen#, Zhedan Zhang, Chen Zhang, Changping Deng, Xikui Tong, Wenyun Zheng*, Meiyan Wang* and Xingyuan Ma*. Development of ZmT-PEG hydrogels through Michael addition reaction and protein self-assembly for 3D cell culture. Biomaterials Science. 2024, DOI: 10.1039/d4bm00643g (IF=5.8; JCR Q1)
3.  Lei Wang, Jiayi Dong, Chenlu Wu, Yiling Wu, Chenyue Yan, Chong Bi, Chengnan Xu, Wenyun Zheng* and Xingyuan Ma*. Development of a synthetic library of humanized nanobodies for targeted IL-6 inhibition. Front. Bioeng. Biotechnol. DOI 10.3389/fbioe.2024.1440150 (IF 6.064; JCR Q2)
4. Chen Zhang, Yunhui Fu, Wenyun Zheng, Feng Chang, Yue Shen, Jinping Niu, Yangmin Wang, and Xingyuan Ma*. Enhancing the Antibody Production Efficiency of Chinese Hamster Ovary Cells through Improvement of Disulfide Bond Folding Ability and Apoptosis Resistance. Cells2024, 13, 1481. doi.org/10.3390/cells13171481. (IF 7.666; JCR Q2)
5. Hui Miao, Yiling Wu, Hao Ouyang, Peiwen Zhang, Wenyun Zheng and Xingyuan Ma*. Screening and construction of nanobodies against human CD93 using phage libraries and study of their antiangiogenic effects. Front. Bioeng. Biotechnol. DOI 10.3389/fbioe.2024.1372245 (IF 6.064; JCR Q2)
6. Jiayue Zhu, Xue Wang, Jianan Zhao, Fang Ji, Jun Zeng, Yanwen Wei, LiLi Xu, Guoying Dong, Xingyuan Ma* and Chengmin Wang*. Genomic characterization and related functional genes of γ-poly glutamic acid producing Bacillus subtilis. BMC Microbiology. (2024) 24:125. doi.org/10.1186/s12866-024-03262-z. (IF=4.2; JCR Q2)
7.  Chen Zhang，Feng Chang，Hui Miao，Yunhui Fu，Xikui Tong，Yu Feng，Wenyun Zheng and Xingyuan Ma*.Construction and application of a multifunctional CHO cell platform utilizing Cre/lox and Dre/rox site-specific recombination systems. Front. Bioeng. Biotechnol. doi.org/10.3389/fbioe.2023.1320841 (IF 6.064; JCR Q2)
8. Changping Deng, Shihui Li, Yuping Liu, Wen Bao, Chengnan Xu, Wenyun Zheng*, Meiyan Wang, Xingyuan Ma*. Split-Cas9-based targeted gene editing and nanobody-mediated proteolysis-targeting chimeras ontogenetically coordinated regulation of Survivin to control the fate of cancer cells. Clinical and Translational Medicine. 2023, Aug; 13(8): e1382. (IF=10.6; JCR Q1)
9. Hui Miao, Chang Liu, Hao Ouyang, Peiwen Zhang, Yuping Liu, Chen Zhang, Changping Deng, Yunhui Fu, Jinping Niu, Wenyun Zheng, Fang You, Yi Yang, Xingyuan Ma*. A nanobody-based molecular toolkit for ubiquitin–proteasome system explores the main role of survivin subcellular localization. Front. Bioeng. Biotechnol., 2023, Jan 20;10:952237. (IF 6.064; JCR Q2)
10. Fabiao Hu, Changping Deng, Yiwen Zhou, Yuping Liu, Tong Zhang, Peiwen Zhang, Zhangting Zhao, Hui Miao, Wenyun Zheng, Wenliang Zhang, Meiyan Wang, Xingyuan Ma*. Multistage targeting and dual inhibiting strategies based on bioengineered tumor matrix microenvironment-mediated protein nanocages for enhancing cancer biotherapy. Bioengineering & Translational Medicine. 2022 Jan 5;7(2): e10290. (IF=11.711; JCR Q1)
11. Changping Deng, Fabiao Hu, Zhangting Zhao, Yiwen Zhou, Yuping Liu, Tong Zhang, Shihui Li, Wenyun Zheng, Wenliang Zhang, Tianwen Wang, Xingyuan Ma*. The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting BIRC5 to Elucidate the Synergistic Pathway of Survivin with P-glycoprotein in Cancer Multi-drug Resistance. Frontiers in Cell and Developmental Biology. 2022 Jan 3; 9: 797005. (IF:6.081; JCR Q2)
12. Shanshan Chen, Changping Deng, Wenyun Zheng, Shihui Li, Yuping Liu, Tong Zhang, Chen Zhang, Yunhui Fu, Hui Miao, Fuzheng Ren and Xingyuan Ma*. Cannabidiol effectively promoted cell death in bladder cancer and the improved intravesical adhesion drugs delivery strategy could be better used for treatment. Pharmaceutics. 2021, 13, 1415. (IF:5.3; JCR Q2)
13. Fabiao Hu,Ting Yan, Wei Guo, Qiuli Liu, Myong Hun Han, Chang Liu,Yuping Liu, Wenyun Zheng*,   Fang You*, Yi Yang, Wenliang Zhang and Xingyuan Ma*. Multiple targeting strategies achieve novel protein drug deliver into cancer cells to proapoptosis lung cancer cell by precisely inhibiting surviving. Nanoscale, 2020, 12, 10623-10638. (IF=8.307; JCR Q1)
14. Fabiao Hu, Ruihuan Zhang, Wei Guo, Ting Yan, Xiujuan He, Fengzhi Hu, Fuzheng Ren, Xingyuan Ma*, Jiandu Lei*, Wenyun Zheng*. PEGylated-PLGA nanoparticles with pH-responsive tannic acid-Fe (III) complexes (TPLGA NPs) for reducing premature drug release on target cancer in vivo. Molecular Pharmaceutics. 2020. doi.org/10.1021/ acs. molpharmaceut. 0c00321. (IF: 5.364; JCR Q2)
15. Zhangting Zhao#, Xingyuan Ma#, Ruihuan Zhang, Fabiao Hu, Tong Zhang, Yuping Liu, Myong Hun Han, Fang You, Yi Yang*, Wenyun Zheng*. A novel liposome-polymer hybrid nanoparticle delivering a multi-epitope self-replication DNA vaccine and its preliminary immune evaluation in experimental animals. Nanomedicine-Nanotechnology Biology and Medicine. 2020;1-15, doi.org/ 10.1016/j.nano.2020.102338 (IF: 6.5; JCR Q2)
16. QianZhi Ni, Zhenhua Chen, Qianwen Zheng, Dong Xie, Jing-Jing Li, Shuqun Cheng*, Xingyuan Ma*. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway. Cancer Science, 2020, 13 January DOI: 10.1111/cas.14331. (IF: 6.518; JCR Q2)
17. Wenpeng Wang, Wenyun Zheng, Dong Wu, Xiujuan He, Haipeng Liu*, Xingyuan Ma*. Precise editing the genome of CHO cell factories with dual-genes for high quality production of heterologous protein by CRISPR/Cas9 technology. ACS Synthetic Biology.2018, 7 (5):1259-1268. (IF: 5.249; JCR Q1)
18. Kefeng Liu, Dan Zheng, Hantian Lei, Jing Liu, Jiandu Lei, * Luying Wang, * and Xingyuan Ma*. Development of Novel Lignin-Based Targeted Polymeric Nanoparticle Platform for Efficient Delivery of Anticancer Drugs. ACS Biomaterials Science & Engineering. 2018, 4 (5): 1730-1737. (IF= 5.8; JCR Q2)
19. Jifan Nie#, Xingyuan Ma#, Fabiao Hu, Hui Miao, Xin Feng, Peiwen Zhang, Myong Hun Han, Fang You, Yi Yang*, Wenlian Zhang, Wenyun Zheng*. Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-α-specific nanobody. Biomedicine & Pharmacotherapy. 2021, (137): 111328. (IF=7.5; JCR Q1)
20. Guo Wei#, Ma Xingyuan#, Fu Yunhui, Liu Chang, Liu Qiuli, Hu Fabiao, Miao Hui, Zhang Tong, Liu Yuping, Han Mingxun, You Fang, Yang Yi*, Zheng Wenyun*. Discovering and Characterizing of Survivin Dominant Negative Mutants with Stronger Pro-apoptotic Activity on Cancer Cells and CSCs. Front Oncol. 2021, 31; 11: 635233. (IF: 6.244; JCR Q2)

1.  专利名称: 一种肿瘤化疗药物的蛋白增敏剂，专利授权号： ZL201010608978.8
2.  专利名称：一种增强多肽药物从细胞内体逃离的蛋白载药系统及其应用；专利授权号：ZL201310178357.4
3.  发明名称：一种内含肽介导的类弹性蛋白纯化重组蛋白的方法，专利授权号：ZL201110236772.1
4.  专利名称：来自LT亚基的细胞穿膜肽LTA2作为细胞内药物运输载体的应用，专利授权号：ZL201410785006.4
5.  专利名称：一种ssDNA-蛋白质酶法交联方法，专利授权号： ZL201310261812.7
6.  发明名称：大肠杆菌热敏毒素B亚单位的真核表达方法，专利授权号：ZL200510027957.6
7.  发明名称：含有HIV转导结构域的生存素突变体及制备方法和应用，专利授权号：ZL200510026847.8
8.  发明名称：一种用于原核分泌、融合表达大肠杆菌热敏毒素B亚单位的载体，专利授权号：ZL200510028084.0
9.  发明名称：一种基于组合自剪切与蛋白支架的生物活性小肽制备方法，专利授权号：ZL201611243905.7
10. 发明名称：抗PD-L1纳米抗体及其应用，专利授权号：ZL202010808068.8
11. 发明名称：基于鲨鱼抗体可变区V-NAR的噬菌体文库及其构建方法,专利授权号：ZL202010808119.7
12. 发明名称：靶向TNF-α的人源化纳米抗体及其制备和用途，专利授权号：ZL202011297844.9
13. 发明名称：负载Survivin双抑制剂的铁蛋白纳米颗粒及其制备方法和应用, 专利授权号: ZL202010397566.8
14. 发明名称：抑制WSSV感染的铁结合蛋白基因Cq-Ferritin及其制备方法与应用,专利授权号: ZL201711076744.1
15. 发明名称：抑制WSSV增殖的半胱天冬氨酸酶基因Cq-caspase及其蛋白抗病毒活性应用，专利授权号:ZL201811089877.7
16. 发明专利：一种口服狂犬病病毒样颗粒疫苗及其制备方法, 专利授权号: ZL202111469820.1
17. 发明名称：一种基因工程改造后的副溶血性弧菌噬菌体裂解酶及其制备方法和应用, 专利授权号:ZL202010095974.8
18. 发明名称：纳米抗体靶向性泛素化降解细胞内源性Survivin组合物及其应用，专利授权号：ZL202010421352.X
19. 发明名称：A PREPARATION METHOD AND APPLICATION OF POLYLACTIC ACID-HUMAN ADIPOSE STEM CELL GEL MICROSPHERE PARTICLES. 专利授权号：S87550

1．国家科技部项目：重点研发计划（合成生物学专项）：（2018YFA0902804负责人）。
2．国家卫健委项目：“新药创制”重大专项：（2009ZX09103-693负责人、2015GKS-470负责人）、（参与：2009ZX09306-008、2004AA2Z3801 [863计划])。
3．国家自然科学基金项目：（主持：32471003【面上】、30873190【面上】、31670944【面上】）、（参与：81673345、30870253、31300660）。
4．国家教育部及JG项目：交叉学科与重大项目培育基金重点项目（主持：WK0913002）、教育部博士点专项基金（主持：20070251011）、教育部新教师科研专项基金(参与：20120074120027)、JG课题2项。
5．上海市项目：“浦江学者”人才计划（主持：13PJD012）、上海市自然科学基金（主持：05ZR14033）、上海市国家新药重大专项配套项目（主持：2009ZX09103-693）、上海市科委生物医药科技重点项目（主持：17431904600、054319928；参与：14431904300）、上海市博士后基金（10R21412000）。
6．其它项目：主持生物反应器工程全国重点实验室重点、面上课题、国际开放合作项目（新加坡）、国内开放合作项目（厦门大学）、华东理工大学引进人才启动基金、企业产学研合作课题等，若干项。

技术咨询